These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7566624)

  • 1. Activation of chronic hepatitis C virus infection by cyclophosphamide in a patient with cANCA-positive vasculitis.
    Arend SM; Hagen EC; Kroes AC; Bruijn JA; van der Woude FJ
    Nephrol Dial Transplant; 1995; 10(6):884-7. PubMed ID: 7566624
    [No Abstract]   [Full Text] [Related]  

  • 2. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
    Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
    Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis].
    Tervaert JW; Stegeman CA
    Ned Tijdschr Geneeskd; 2003 Nov; 147(46):2265-7. PubMed ID: 14655291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
    Sanders JS; Slot MC; Stegeman CA
    N Engl J Med; 2003 Nov; 349(21):2072-3; author reply 2072-3. PubMed ID: 14627795
    [No Abstract]   [Full Text] [Related]  

  • 5. Pneumocystis carinii pneumonia during immunosuppressive therapy for antineutrophil cytoplasmic autoantibody-positive vasculitis.
    Huynh-Do U; Gantenbein H; Binswanger U
    Arch Intern Med; 1995 Apr; 155(8):872-4. PubMed ID: 7717797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
    Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis (CYCLOPS study)].
    Kötter I
    Z Rheumatol; 2009 Sep; 68(7):575-7. PubMed ID: 19652987
    [No Abstract]   [Full Text] [Related]  

  • 8. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
    Lapraik C; Watts R; Bacon P; Carruthers D; Chakravarty K; D'Cruz D; Guillevin L; Harper L; Jayne D; Luqmani R; Mooney J; Scott D;
    Rheumatology (Oxford); 2007 Oct; 46(10):1615-6. PubMed ID: 17804455
    [No Abstract]   [Full Text] [Related]  

  • 9. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
    Levine SM
    Ann Intern Med; 2010 Jan; 152(1):65; author reply 65. PubMed ID: 20048281
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse effects of therapy for ANCA-associated vasculitis.
    Turnbull J; Harper L
    Best Pract Res Clin Rheumatol; 2009 Jun; 23(3):391-401. PubMed ID: 19508946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ANCA-positive vasculitis of the skin and kidneys associated with acne conglobata].
    Manz B; Rytter M; Mittag M; Seidel W; Nenoff P
    Hautarzt; 2002 Nov; 53(11):730-4. PubMed ID: 12402135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis.
    Marinaki S; Kälsch AI; Grimminger P; Breedijk A; Birck R; Schmitt WH; Weiss C; van der Woude FJ; Yard BA
    Nephrol Dial Transplant; 2006 Jul; 21(7):1825-32. PubMed ID: 16567340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
    Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
    Rheumatology (Oxford); 2006 Jun; 45(6):724-9. PubMed ID: 16399845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients.
    Harper L; Savage CO
    Rheumatology (Oxford); 2005 Apr; 44(4):495-501. PubMed ID: 15613403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retroperitoneal fibrosis with antineutrophil cytoplasmic antibodies.
    Kaipiainen-Seppänen O; Jantunen E; Kuusisto J; Marin S
    J Rheumatol; 1996 Apr; 23(4):779-81. PubMed ID: 8730147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy?
    Flossmann O; de Groot K
    Nat Clin Pract Nephrol; 2007 May; 3(5):236-7. PubMed ID: 17457358
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies.
    Vassilopoulos D; Calabrese LH
    Arthritis Rheum; 2002 Mar; 46(3):585-97. PubMed ID: 11920393
    [No Abstract]   [Full Text] [Related]  

  • 18. MPO-ANCA-associated pulmonary-renal vasculitis in a patient with diabetes mellitus.
    Keven K; Akar H; Kutlay S; Nergizoglu G; Erbay B; Erturk S
    J Nephrol; 2002; 15(6):720-3. PubMed ID: 12495292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies.
    Brijker F; Magee CC; Tervaert JW; O'Neill S; Walshe JJ
    Clin Nephrol; 1999 Dec; 52(6):344-51. PubMed ID: 10604641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.